Johnson & Johnson, Lam Research and Seagate lead today's analyst picks as strong results, AI demand and growth outlooks drive the latest research.

One of Rhode Island's most-wanted fugitives was captured Monday after apparently hiding out for 20 years as a biotech executive.

Johnson & Johnson beat Q2 estimates as growth in key drugs, MedTech and its pipeline helps offset Stelara headwinds. Read what's driving outlook.

You can be forgiven for doing a double-take on Intuitive Surgical (ISRG) on Friday. The company posted second-quarter revenue of $2.89 billion, up 19% from a year ago and comfortably ahead of Wall Street estimates. Yet the stock ended the day down 14.1%, closing at a new 52-week low.

The healthcare giant's pharma division is booming, but analysts on its latest call wanted to know if that's enough to cover for a sudden slowdown in MedTech.

The surgical robotics giant beat estimates, but a moderation in its core US market has investors questioning the whole story.

Jim Cramer took a bullish stance on Alibaba despite its brutal year-to-date slide, pairing the call with two steady compounders he thinks belong in every long-term portfolio. Here is what he told one caller sitting on a sizable BABA position.

Management lifted its profit outlook, and investors have more than quadrupled that bet. The question now is what they're really paying for.

JNJ raised its 2026 outlook after strong Q2 results, but can new medicines and pipeline strength outweigh patent losses and MedTech challenges?

LQDA, BILL and Colgate-Palmolive highlight recent Zacks picks as multiple portfolios outperformed or posted strong stock gains despite market volatility.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

Despite its enticing dividend yield and relatively attractive valuation, J&J Snack Foods' (JJSF) stock may represent a value trap.

For many cancers now, the standard treatment is chemotherapy plus an immunotherapy such as Merck Keytruda, the best-selling drug in the world. Many think it will pair two innovations: precisely-targeted chemo drugs known as antibody-drug conjugates, or ADCs, and augmented immunotherapies in the form of bispecific antibodies. Bispecific antibodies are being tested by Bristol Myers Squibb (with its partner BioNTech ), AstraZeneca and the biotech firm Summit Therapeutics ADCs have already rung up big sales for Astra, Pfizer Gilead Sciences and Roche Holding but Merck has a strong contender in development.

J&J has more than 28 sources of blockbuster revenue.

They can help stabilize your portfolio in these otherwise volatile times.

DePuy Synthes, part of Johnson & Johnson MedTech, has acquired spine surgery company Expanding Innovations, adding new expandable interbody technologies to its portfolio. Johnson & Johnson has received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in electrophysiology, expanding its ablation technology offering. For investors watching Johnson & Johnson, ticker NYSE:JNJ, these MedTech moves arrive with the stock at $253.04 and a value_score of 2. The company has recorded...

All three pharma giants have left the S&P 500 in the dust, but surging returns and strong fundamentals tell very different stories about where each stock goes from here.

A portfolio paying $55,000 this year feels useful today, but inflation has a way of quietly making that same paycheck feel smaller every year you spend it. The yield you choose right now could either protect your retirement income or slowly hollow it out.

Most investors chase the biggest dividend check they can find today, but that instinct quietly sabotages the income they could be collecting a decade from now. The math behind a smarter approach is almost offensively simple once you see it.

Headline inflation keeps rising faster than Social Security adjustments, quietly shrinking what retirement actually buys. A small, dedicated portfolio sleeve could fund those annual increases entirely from income, but the tier you choose changes everything about how much capital you actually need.

Most investors chase the biggest yield they can find, but the portfolio that actually grows your income year after year is built on a completely different logic. Here is how dividend math quietly delivers something that usually requires a performance review.

Every new tariff headline, rate decision, and earnings miss seems to demand a financial response, and that constant pressure is exhausting. There is a way to build a portfolio so sturdy that the daily news cycle loses its grip on your nerves.

With 10-year Treasuries near 4.62%, VYM's $94.6 billion portfolio faces a real test from risk-free yields, and two familiar names inside the fund are quietly raising red flags about future income growth.

SPYI's 12% annualized payout looks generous until you check what two converging macro forces are quietly doing to the premium engine that funds it.

Four thousand dollars a month can cover a paid-off house, groceries, utilities, insurance, and modest travel in many parts of the country. It is also more than the $3,208 average monthly Social Security benefit SSA estimates for an aged couple, both receiving benefits, in January 2026. A portfolio producing another $4,000 a month can materially ... Can a Conservative Portfolio Really Generate $4,000 a Month in Retirement Income?

JNJ beats Q2 estimates and raises 2026 guidance, but shares fall as MedTech misses expectations. Find out what weighed on the unit and what's next.

This healthcare giant is forecasting a significant acceleration, but you are being asked to look past a slowdown in its biggest growth engine and other execution hurdles.

Intuitive Surgical stock falls sharply after earnings, but this analyst believes investors are missing part of the picture.

A portfolio that pays $27,000 a year in dividends sounds modest. Left alone for a little more than a decade of steady dividend growth, that same income stream can quietly grow toward $66,000 without a single additional dollar of savings. That is the basic appeal of dividend growth investing: the arithmetic of today’s yield matters, ... Growing an Income Tree: From $27,000 to $66,000

Citi analysts laid out the appeal of biopharma stocks, with the NYSE Arca Pharmaceutical Index outrunning the S&P in the last month.

Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.

Few things ruin a Saturday morning faster than the words “your timing chain is going.” Car repair bills arrive unannounced, cost more than expected, and have a way of landing the same week as property taxes or insurance renewals. The fix is a small, dedicated slice of capital whose only job is to absorb those ... The Portfolio That Pays All Your Car Repairs For Life

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.

Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.

Eli Lilly (LLY) is acquiring AtaiBeckley (ATAI) — a biopharmaceutical company that specializes in psychedelic-based mental health treatments — in a new deal valued at up to $3.8 billion. Mizuho Americas healthcare equity strategist Jared Holz weighs in on this deal and what it represents for M&A in the broader pharma space.

Johnson & Johnson's (JNJ) Innovative Medicine segment momentum is building into 2027, with the compa

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Johnson & Johnson raises its 2026 outlook after Q2 earnings and revenues beat estimates, driven by Innovative Medicine strength and pipeline momentum.

Abbott’s (ABT) latest financial disclosure reveals a significant strategic evolution that market participants often overlook amidst the focus on quarterly beats. The company is actively executing a structural pivot, shifting its capital allocation and growth dependency away from the volatile Nutrition segment toward high-margin, innovation-led MedTech and specialized diagnostics.

While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth occurring in another.

While the market focuses on a single class of blockbuster drugs, a different story is unfolding inside the company. Lilly’s immunology, oncology, and neuroscience medicines are quietly compounding at a blistering pace. These other therapeutic areas collectively grew by 160% last quarter, a rate that suggests a much broader growth engine is taking shape.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

Abbott Laboratories posted slightly better-than-expected second-quarter earnings and raised its full-year profit outlook.

Find insight on Johnson & Johnson, Rubber Industries, and more in the latest Market Talks covering health care.

Twenty thousand dollars a month in dividends means $240,000 a year that has to arrive whether the market cooperates or not. Reaching it is a math problem before it is a stock-picking problem, and the math gets uncomfortable fast when you compare that target with current yields. The core equation is unforgiving: annual income divided ... The Portfolio Blueprint for Building $20,000 a Month in Dividend Income

J&J’s fast-growing Inlexzo bladder-cancer franchise could make IBRX either strategically attractive or a direct rival.

Investors didn't seem to think so after the company published it.

How do you find the best dividend stocks to buy? Income investors know there's no substitute for regular dividend increases over the long haul.

Wholesale inflation data cooled while major earnings season kicked off positively, lifting stocks across the board, today, July 15, 2026.